多西他赛联合卡培他滨与吉西他滨联合顺铂治疗三阴乳腺癌的效果比较

Comparison of effects of Docetaxel combined with Capecitabine and Gemcitabine combined with Cisplatin in treatment of triple negative breast cancer

目的:探讨吉西他滨联合顺铂(GP方案)与多西他赛联合卡培他滨(TX方案)对三阴乳腺癌患者临床治疗效果的差异,并观察患者的预后。方法:选取72例三阴乳腺癌患者为研究对象,采用随机数字表法分为对照组和研究组各36例。对照组采用TX化疗方案,研究组采用GP化疗方案。观察两组患者的不良反应,评估患者的近期疗效;治疗结束后进行随访,评估患者的中位总生存期。结果:研究组患者的客观缓解率66.67%和疾病控制率83.33%均高于对照组的41.67%和58.33%,差异有统计学意义(P<0.05);研究组患者中位总生存期(OS)为21.4个月,高于对照组的15.9个月,差异具有统计学意义(P<0.05);两组不良反应比较,对照组患者的食欲下降发生率为36%,低于研究组的69%,差异有统计学意义(P<0.05)。结论:吉西他滨联合顺铂较多西他赛联合卡培他滨对三阴乳腺癌的治疗更有优势,不良反应患者可耐受,在临床上可作为治疗三阴乳腺癌患者的有效治疗方案之一。

Objective: To investigate differences in clinical effects between Docetaxel combined with Capecitabine (TX regimen) and Gemcitabine combined with Cisplatin (GP regimen) in treatment of patients with triple negative breast cancer, and to observe the prognosis of the patients. Methods: 72 patients with triple negative breast cancer, who were treated in Liaoyang City Central Hospital from April 2013 to May 2016, were selected and divided into control group (TX chemotherapy regimen) and study group (GP chemotherapy regimen) by using the random number table method, 36 cases in each group. The adverse reactions were observed and recorded, and the short-term curative effects were evaluated. All the patients were followed up to assess the median overall survival after the treatment. Results: The objective remission rate and the disease control rate of the study group (66.67% and 83.33%) were higher than those of the control group (41.67% and 58.33%), and the differences were statistically significant (P<0.05). The median overall survivals (OS) of the control group and the study group were 15.9 months and 21.4 months, respectively, and the difference was statistically significant (P<0.05). The incidence of loss of appetite in the control group was lower than that in the study group (36% vs 69%), and the differences were statistically signi ficant (P<0.05). Conclusions: Gemcitabine combined with Cisplatin has more advantages over Docetaxel combined with Capecitabine in the treatment of triple negative breast cancer, and the adverse reactions can be tolerated. The former can be used as one of the effective treatments for the patients with triple negative breast cancer.